NCT04720768 2024-01-05
CELEBRATE
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Unknown
Clinical Trials
5 trialsNCT05767879 2023-03-14
(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma
Leiden University Medical Center
Phase 2 Unknown
NCT05103891 2021-12-01
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
Pierre Fabre Medicament
Phase 1 Unknown
NCT05097378 2021-10-28
PREMIUM
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Unknown
NCT04292119 2021-03-10
Lorlatinib Combinations in Lung Cancer
Massachusetts General Hospital
Phase 1/2 Unknown